MATINAS BIOPHARMA HOLDINGS I (MTNB) Stock Price, Quote, News and Overview
NYSEARCA:MTNB - NYSE Arca - US5768103039 - Common Stock - Currency: USD
MTNB Quote, Performance and Key Statistics
0.64
+0.06 (+9.97%)
The current stock price of MTNB is 0.64 USD. In the past month the price increased by 7.2%. In the past year, price decreased by -94.43%.
MTNB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About MTNB
Company Profile
Matinas BioPharma Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Bedminster, New Jersey and currently employs 32 full-time employees. The company went IPO on 2014-06-03. Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The firm is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. The company is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. The company is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFα.
Company Info
MATINAS BIOPHARMA HOLDINGS I
Suite 302, 1545 Route 206 South
Bedminster NEW JERSEY 07921 US
CEO: Jerome D. Jabbour
Employees: 32
Company Website: https://www.matinasbiopharma.com/
Investor Relations: http://www.matinasbiopharma.com/investors
Phone: 19084431860
MATINAS BIOPHARMA HOLDINGS I / MTNB FAQ
What is the stock price of MATINAS BIOPHARMA HOLDINGS I today?
The current stock price of MTNB is 0.64 USD. The price increased by 9.97% in the last trading session.
What is the ticker symbol for MATINAS BIOPHARMA HOLDINGS I stock?
The exchange symbol of MATINAS BIOPHARMA HOLDINGS I is MTNB and it is listed on the NYSE Arca exchange.
On which exchange is MTNB stock listed?
MTNB stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for MATINAS BIOPHARMA HOLDINGS I stock?
7 analysts have analysed MTNB and the average price target is 30.6 USD. This implies a price increase of 4681.25% is expected in the next year compared to the current price of 0.64. Check the MATINAS BIOPHARMA HOLDINGS I stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MATINAS BIOPHARMA HOLDINGS I worth?
MATINAS BIOPHARMA HOLDINGS I (MTNB) has a market capitalization of 3.26M USD. This makes MTNB a Nano Cap stock.
How many employees does MATINAS BIOPHARMA HOLDINGS I have?
MATINAS BIOPHARMA HOLDINGS I (MTNB) currently has 32 employees.
What are the support and resistance levels for MATINAS BIOPHARMA HOLDINGS I (MTNB) stock?
MATINAS BIOPHARMA HOLDINGS I (MTNB) has a support level at 0.6 and a resistance level at 0.65. Check the full technical report for a detailed analysis of MTNB support and resistance levels.
Is MATINAS BIOPHARMA HOLDINGS I (MTNB) expected to grow?
The Revenue of MATINAS BIOPHARMA HOLDINGS I (MTNB) is expected to decline by -100% in the next year. Check the estimates tab for more information on the MTNB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MATINAS BIOPHARMA HOLDINGS I (MTNB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MTNB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MTNB, evaluating the profitability, health, valuation and growth aspects
- MATINAS BIOPHARMA HOLDINGS I (MTNB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MATINAS BIOPHARMA HOLDINGS I (MTNB) Sales and EPS estimates to see what analysts future expectations are.
- MATINAS BIOPHARMA HOLDINGS I (MTNB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MATINAS BIOPHARMA HOLDINGS I (MTNB) Insider and Institutional Ownership to learn about the owners and their transactions.
- MATINAS BIOPHARMA HOLDINGS I (MTNB) Stock Chart to make your own analysis
- MATINAS BIOPHARMA HOLDINGS I (MTNB) Latest news and press-releases to stay up to date.
Does MATINAS BIOPHARMA HOLDINGS I (MTNB) stock pay dividends?
MTNB does not pay a dividend.
When does MATINAS BIOPHARMA HOLDINGS I (MTNB) report earnings?
MATINAS BIOPHARMA HOLDINGS I (MTNB) will report earnings on 2025-03-25, after the market close.
What is the Price/Earnings (PE) ratio of MATINAS BIOPHARMA HOLDINGS I (MTNB)?
MATINAS BIOPHARMA HOLDINGS I (MTNB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.35).
What is the Short Interest ratio of MATINAS BIOPHARMA HOLDINGS I (MTNB) stock?
The outstanding short interest for MATINAS BIOPHARMA HOLDINGS I (MTNB) is 6.33% of its float. Check the ownership tab for more information on the MTNB short interest.
MTNB Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MTNB. When comparing the yearly performance of all stocks, MTNB is a bad performer in the overall market: 94.95% of all stocks are doing better.
MTNB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MTNB. While MTNB seems to be doing ok healthwise, there are quite some concerns on its profitability.
MTNB Financial Highlights
Over the last trailing twelve months MTNB reported a non-GAAP Earnings per Share(EPS) of -4.35. The EPS increased by 20.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -102.7% | ||
| ROE | -133.92% | ||
| Debt/Equity | 0 |
MTNB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 46% to MTNB. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 20.63% and a revenue growth -100% for MTNB